IBIO
What one share of Ibio holds
Pharmaceutical Preparations
We believe the future treatment for obesity lies not just in overall weight loss, but in the quality, durability, and tolerability of weight loss. Current interventional therapies, such as glucagon-like peptide-1 (“GLP-1”) receptor agonists have ushered in a breakthrough era, yet challenges remain: muscle loss, fat regain after treatment cessation, and long-term tolerability.
Ibio’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.32 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.23 |
| Cash and investments | $1.01 |
| Book value | $1.54 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $22.11 | −$820.45 | $74.23 | −$812.82 | — | $500.12 |
| 2018 | $20.88 | −$769.68 | $43.93 | −$677.92 | — | $503.92 |
| 2019 | $53.31 | −$471.65 | $24.31 | −$393.51 | — | $61.11 |
| 2020 | $13.04 | −$304.64 | $8.58 | −$114.84 | — | — |
| 2021 | $6.06 | −$59.98 | $12.58 | −$89.42 | — | $249.19 |
| 2022 | $4.32 | −$115.36 | $16.81 | −$102.76 | — | $145.49 |
| 2023 | $0.00 | −$106.23 | $9.38 | −$59.11 | — | $15.15 |
| 2024 | $0.06 | −$6.50 | $0.05 | −$4.90 | — | — |
| 2025 | $0.04 | −$1.75 | $0.00 | −$1.46 | — | $0.77 |
| 2026 | $0.00 | −$0.32 | $0.01 | −$0.23 | — | $1.54 |